Blau Farmaceutica (BSP:BLAU3) Debt-to-Revenue : 0.39 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Blau Farmaceutica Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Blau Farmaceutica's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was R$75 Mil. Blau Farmaceutica's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was R$534 Mil. Blau Farmaceutica's annualized Revenue for the quarter that ended in Dec. 2023 was R$1,550 Mil. Blau Farmaceutica's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.39.

Blau Farmaceutica Debt-to-Revenue Historical Data

The historical data trend for Blau Farmaceutica's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blau Farmaceutica Debt-to-Revenue Chart

Blau Farmaceutica Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

0.29

0.59

0.27

0.22

0.44

Blau Farmaceutica Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															0.21	0.31	0.17	0.42	0.39

Competitive Comparison of Blau Farmaceutica's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Blau Farmaceutica's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Blau Farmaceutica's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Blau Farmaceutica's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Blau Farmaceutica's Debt-to-Revenue falls into.

Blau Farmaceutica Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Blau Farmaceutica's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(75.018	+	533.52)	/	1372.633
	=	0.44

Blau Farmaceutica's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(75.018	+	533.52)	/	1549.9
	=	0.39

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

Blau Farmaceutica Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Blau Farmaceutica's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Blau Farmaceutica (BSP:BLAU3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Blau Farmaceutica SA (BSP:BLAU3) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Rodovia Raposo Tavares, No. 2833, Km 30.5, Barro Branco, Cotia, SP, BRA, 06705-030

Website

https://www.blau.com

Blau Farmaceutica SA is engaged in the manufacturing, development and commercialization of complex private-label drugs for the institutional segment. The Company's business activities cover institutional and retail segments, and are divided into four units: 1) Biologicals are a heterogeneous class of products that can be produced using raw materials from biological materials and biotechnological procedures. 2) Oncology line is made up of oral and injectable drugs intended for treating cancer, which encompasses a number of therapeutic classes. 3) Specialties line is made up of products that are used in the hospital's daily routine, in the specialized treatments for infectious diseases and special treatments. 4) Others consist of prescription and non-prescription over-the-counter drugs.

Blau Farmaceutica (BSP:BLAU3) Headlines

No Headlines